Depression Medication Study (Shoreline)
Depression is a serious but common condition that affects how you think, feel, and carry out your daily activities. We are studying an investigational oral medication to see if it reduces symptoms of moderate-to-severe depression in adults.
The Shoreline Study is a Phase 3, open-label, 1-year study of the safety and need for re-treatment with SAGE-217 in adults with major depressive disorder (MDD), as assessed by the Hamilton Depression Rating Scale (HAM-D).
Digital Mental Health Tools Study (IDEA)
The IDEA study offers people self-help tools to improve their symptoms of depression and promote wellbeing such as a smartphone app, a computer-based online program, or an educational website and try to understand whether the tools are helpful to them.
Sixty depressed patients will be asked to select one electronic Mental Health (e-MH) resource from three offered in this pilot study. A Depression Care Manager will also be paired with patients, in part to motivate continued use of the resources, since lack of persistent use of e-MH resources has been a barrier. This study will provide real-world data on the implementation and effectiveness of e-health resources in a traditional healthcare delivery model.
Spravato Ketamine Depression Study
The purpose of this study is to evaluate the efficacy, safety, and tolerability of an investigational medication, (SPRAVATOTM)
A clinical trial for Esketamine Nasal Spray, SPRAVATOTM, as a standalone therapy for adult participants with treatment-resistant depression (TRD). Esketamine nasal spray (SPRAVATOTM) is currently approved in the United States for use with an oral antidepressant for the treatment of TRD in adults.